Blog

Peripheral afferent neurons—nerves that send signals from all areas of the body to the central nervous system (brain and spinal cord)—are known to infiltrate and grow within malignant bone tumors called osteosarcomas, often accompanied by severe pain.

In a study published in Proceedings of the National Academy of Sciences, a multicenter research team led by Johns Hopkins Medicine reports that two analgesic drugs, bupivacaine and rimegepant, which are used to inhibit the formation and functioning of these neurons, not only relieve tumor-associated pain in laboratory mice, but also slow the unchecked growth of the cancer.

“Our findings suggest that these two medications—already approved by the U.S. Food and Drug Administration [FDA] for relieving nerve pain [bupivacaine] and migraines [rimegepant]—might one day be repurposed as anti-tumor therapies,” says study lead author Sowmya Ramesh, Ph.D., a postdoctoral researcher in pathology at the Johns Hopkins University School of Medicine.

Research from the University of Gothenburg, Sweden, clarifies the complex interaction between gut bacteria and irritable bowel syndrome (IBS). Experiments demonstrate that gut bacteria can produce the important substance serotonin. The finding may lead to future treatments.

IBS is a common gastrointestinal disorder, more common in women, with symptoms such as abdominal pain, constipation or diarrhea. The cause of the disease is not clear, but the intestinal environment, including the gut microbiota and serotonin, appear to be important factors.

Serotonin is best known as a neurotransmitter in the brain, but over 90% of the body’s serotonin is produced in the gut, where it controls bowel movements via the enteric nervous system, sometimes called the “gut–brain.”